NEU

2.50%

$15.59 neuren pharmaceuticals limited

Share Price, page-1050

First 1050 Last

Share
Profile

Follow
Tony barber

6,467 Posts.

707

23/02/22

22:26

Post #: 59774057
Share

Originally posted by Potstock88 ↑

Tony Barber - I answered your "will FDA approval occur" query quite a while ago and you never replied. I remember it quite distinctly because I was surprised how superficial your knowledge was, leaving you with no substance left to respond, so you just ignored me.

The "will FDA approval happen though?" is the weakest argument downrampers have against NEU. Just have a look at that analyst thinking NEU has dropped some bullshit-% chance at FDA approval...lol. Problem is it is the ONLY argument left to downramp this stock, so it is used over and over again, at different time intervals.

Could you please list the reasons why NEU wont get FDA approval? Thanks.

Everyone else - FDA
Here is some more FDA collusion with the pharmaceutical industry, if Neuren's phase-3 results are somehow not good enough for some. The reason why I give these examples is to illustrate that the FDA WANTS to approve new drugs...not that I support such collusion/corruption.

The FDA Director of Psychiatric Products, Thomas Laughren encouraged the FDA approval committee to listen to AstraZenica, that their drug Seroquel, is safe, despite evidence from outside health experts suggesting it was causing sudden cardiac deaths associated with drug interactions. The FDA approval committee agreed with Thomas Laughren, and IGNORED the expert health advice. They approved Seroquel with zero labelling or recommendations about the risk of cardiac arrest. It was later found out that Seroquel was 100% the cause of sudden cardiac arrest and death, so the FDA amended this by adding a warning label...

Thomas Laughren then left the FDA and formed his OWN agency that worked to help pharmaceutical companies, including AstraZenica itself, navigate the FDA and gain approvals....

On what planet does NEU not get approved is beyond me. If it doesn't get approval, the FDA will simply give ACADIA a path on how to get approval. I just can not think of a reason why it wont get approved that has not already been addressed. Tony will help us all I am sure.

GLTAH.

Expand

Wow. I just read your complete post.
Down rampers? Seriously? One of my best real life friends posts here, and has a lot in it.

Do you think I'm waiting for $2.20 or something? If so you've lost the plot.

If you believe the FDA will automatically approve this for manufacturing and distribution then just sell everything you have and put it into neu.

But you won't. Because in the back recesses of your mind you know why.

I have never said trof won't get approval. Never.
But it is not a given.

If you think it is, then sell the roof your kids live under and go for it. All up to you.

NEU Price at posting: $3.88 Sentiment: Hold Disclosure: Not Held
2 Upvote

0 Great analysis

Reply

Top Stories

VYS

Vysarn acquires Waste Water Services Pty Ltd for $7.5M; WWS to become subsidiary as expansion continues

PYC

PYC achieves key designation for drug aiming to treat blinding eye disease ADOA

Consumer Staples Shine Amid Retail Slump – Key Stocks to Watch

TBN

Tamboran kicks off Shenandoah South pilot project with SS-2H well spud

CYM

WA Nifty copper project steps closer to restart with Cyprium Metals inking $40M loan from Glencore

LLC

Lendlease sells off US east coast construction operations in latest global divestment push

HLX

Helix investor makes partial takeover bid, proposing board changes

Week 35 Wrap: HotCopper’s top watched; ‘iron ore winter’ has started; Oz inflation @ 3.5% MoM; Harris fracking flip

HVN

Consumers cautious according to Harvey Norman, as profit slumps 35% in FY24

CCO

The Calmer Co’s Anthony Noble reflects on record breaking FY24

There are more pages in this discussion • 10,461 more messages in this thread...

First 1050 Last

Add NEU (ASX) to my watchlist

(20min delay)
Last $15.59		Change 0.380(2.50%)		Mkt cap ! $1.992B

Open	High	Low	Value	Volume
$15.51	$15.82	$15.46	$11.26M	722.0K

Buyers (Bids)

No.	Vol.	Price($)
1	696	$15.59

Sellers (Offers)

Price($)	Vol.	No.
$15.67	6942	8

View Market Depth

No.	Vol.	Price($)
1	64	15.570
1	320	15.510
1	181	15.450
1	530	15.300
1	2500	15.250

Price($)	Vol.	No.
15.670	2340	1
15.800	20	1
15.810	316	1
15.850	800	1
15.900	500	1

Last trade - 16.10pm 30/08/2024 (20 minute delay)

NEU (ASX) Chart

Share Price, page-1050

Vysarn acquires Waste Water Services Pty Ltd for $7.5M; WWS to become subsidiary as expansion continues

PYC achieves key designation for drug aiming to treat blinding eye disease ADOA

Consumer Staples Shine Amid Retail Slump – Key Stocks to Watch

Tamboran kicks off Shenandoah South pilot project with SS-2H well spud

WA Nifty copper project steps closer to restart with Cyprium Metals inking $40M loan from Glencore

Lendlease sells off US east coast construction operations in latest global divestment push

Helix investor makes partial takeover bid, proposing board changes

Week 35 Wrap: HotCopper’s top watched; ‘iron ore winter’ has started; Oz inflation @ 3.5% MoM; Harris fracking flip

Consumers cautious according to Harvey Norman, as profit slumps 35% in FY24

The Calmer Co’s Anthony Noble reflects on record breaking FY24

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Share Price, page-1050

Top Stories

Vysarn acquires Waste Water Services Pty Ltd for $7.5M; WWS to become subsidiary as expansion continues

PYC achieves key designation for drug aiming to treat blinding eye disease ADOA

Consumer Staples Shine Amid Retail Slump – Key Stocks to Watch

Tamboran kicks off Shenandoah South pilot project with SS-2H well spud

WA Nifty copper project steps closer to restart with Cyprium Metals inking $40M loan from Glencore

Lendlease sells off US east coast construction operations in latest global divestment push

Helix investor makes partial takeover bid, proposing board changes

Week 35 Wrap: HotCopper’s top watched; ‘iron ore winter’ has started; Oz inflation @ 3.5% MoM; Harris fracking flip

Consumers cautious according to Harvey Norman, as profit slumps 35% in FY24

The Calmer Co’s Anthony Noble reflects on record breaking FY24

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News